Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).

Article Details

Citation

Copy to clipboard

Lee SH

Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).

Arch Pharm Res. 2011 Aug;34(8):1223-6. doi: 10.1007/s12272-011-0821-9.

PubMed ID

21910042 [ View in PubMed

]

Abstract

Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Olinvacimab	Vascular endothelial growth factor receptor 2	Protein	Humans	Yes	Antibody Regulator	Details